Subcutaneous Rituximab Improves Progression-Free Survival in Low-Tumor Burden Follicular Lymphoma
Researchers sought to determine whether subcutaneous rituximab would improve survival in patients with low-tumor burden follicular lymphoma.
Diagnosis & Disease Information
Associations Between Cancer and COVID-19 Death “More Substantial” in Women
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
Cancer Risk Increased With Exposure to Four or More CT Scans by Age 18
Increased risk of intracranial tumors, leukemia, and lymphoma by age 25 seen with exposure to four or more CT scans during childhood.
Crizotinib With Chemotherapy Prevents Relapse in Pediatric Patients With ALK1 ALCL, Has Thromboembolic Risk
Researchers sought to determine whether adding crizotinib to chemotherapy would improve responses in pediatric patients with ALCL.
Promising Efficacy Seen With Lisocabtagene Maraleucel in LBCL
Researchers sought to determine the efficacy of lisocabtagene maraleucel in LBCL compared with standard of care for primary refractory or early relapsed disease.
Bispecific CAR T-Cell Therapy Has “Robust” Activity in Non-Hodgkin Lymphoma
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
Curative Potential Seen With Tafasitamab in R/R DLBCL
Researchers sought to determine whether tafasitamab would lead to durable responses in patients with R/R DLBCL.
Polivy Combination Therapy Approved for Previously Untreated DLBCL
Polivy is a CD79b-directed antibody and microtubule inhibitor conjugate.
Promising Antitumor Activity Seen With Sugemalimab in Extranodal NK Cell or T-Cell Lymphoma
Researchers sought to determine the safety and efficacy of sugemalimab in patients with relapsed/refractory extranodal natural killer cell or T-cell lymphoma.
Survey Shows Oncologists Vary in Guideline Adherence for PET-Adapted Approaches in Classic Hodgkin Lymphoma
Researchers sought to determine adherence to guidelines for oncologists utilizing PET-adapted strategies for patients with III/IV classic Hodgkin lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...